David Hutton

At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.

Dr Jill Hopkins discusses results from phase 3a of the Merlin trial for brolucizumab as a treatment for wet AMD and provides updates on KESTREL and KITE trials for the treatment of diabetic macular oedema.

The agreement includes Europe, Commonwealth of Independent States countries, China, India, parts of Latin America and the Oceania countries.

New cell therapy drug makes treatment of corneal endothelial disease more accessible.

The VIVID study focuses on three novel topical ophthalmic formulations under investigation for the treatment of presbyopia.

The Children’s Vision Equity Alliance was created to improve access in children’s vision and eye health, working to advance equity in children’s vision and eye health through education, policies and partnerships.

ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.

The American Academy of Ophthalmology's annual meeting will proceed November 12 to 15 in New Orleans, Louisiana.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia.

Susvimo, formerly called the Port Delivery System with ranibizumab, is a first-of-its-kind therapeutic approach for wet AMD and may help people with the disease maintain their vision with as few as two treatments per year.

As the world comes together to shine a global spotlight on blindness and vision impairment on World Sight Day, several global organizations and companies are stepping up to increase awareness of eye health, including the importance of regular examinations by an ophthalmologist or optometrist.

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

Investigators at Dartmouth College have found that eye contact during a conversation makes the discussion more appealing to its participants.

American Society of Retina Specialists (ASRS) meeting offers scientific sessions, symposia, discussion groups, opportunities for attendees.

The eyeglasses were reportedly designed to help the wearer reach enlightenment and drive away evil, according to Sotheby’s London, which will host the auction next month.

A new study reveals that children of mothers with diabetes during pregnancy have an increased risk of eye problems.

Science fiction is quickly becoming science fact as a team of German scientists found that a small, lab-grown brain cell cluster that developed fundamental eye structures.

An international research team has shown that optogenetic therapy has helped to partially regain visual function in a patient with retinitis pigmentosa. This is a milestone towards a gene therapy that could restore vision.

Vyluma Inc. will focus on the development and commercialization of therapies to treat ophthalmic diseases, including paediatric myopia.

Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).

Dr Mohamed Abou Shousha and Dr Richard Parrish II discuss their ARVO 2021 presentation regarding a study analyzing visual field measurements using the Heru Visual Field Multi-platform application downloaded on two different commercially available augmented reality devices.

Dr. Michael Mbagwu speaks on the highlights of his virtual 2021 ARVO presentation regarding the development of an algorithm tool that links patient imaging to their clinical data, specifically within the AAO IRIS Registry.

Dr Theodore Leng discusses the highlights from his presentation on "AAO IRIS Registry Data Replicates VIEW 1 and VIEW 2 Clinical Trial Outcome Data," during the virtual 2021 ARVO meeting.

Dr. Daniel F. Kiernan discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.

Dr Glenn J. Jaffe discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.

A cluster of COVID-19 positive patients developed endophthalmitis, and investigators are searching for a link.

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Tanner Ferguson, MD, Cole Eye Institute, discusses findings from the study "Trabecular Micro-bypass Stent Implantation (iStent)" + Phacoemulsification in PXG: Six-Year Outcomes," during the virtual AAO 2020 meeting.

John A. Hovanesian, MD, discusses the highlights of his presentation on a clinical study evaluating dexamethasone vs prednisolone acetate 1% in controlling postop pain/inflammation in sequential cataract surgery patients.